Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Jun. 01, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 02, 2016
Successor [Member]
Total rent				$ 3,200
Rent expense		$ 18,138		85,811
Monthly sub leased				7,834
Estimated fair value of contingent payments, net		305,913		305,913		$ 424,511
Contingent cash payment							$ 500,000
Successor [Member] \| Third Party [Member]
Monthly sub leased	$ 4,000
Successor [Member] \| ASK Gold [Member]
Earn out payments				23,578
Predecessor [Member]
Rent expense			$ 22,510		$ 70,723
Estimated fair value of contingent payments, net		$ 71,442		71,442
Earn out payments				23,578
Reimbursement Expenses					$ 95,020
Predecessor [Member] \| ASK Gold [Member]
Earn out payments				$ 47,156